Overview

Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells

Status:
Withdrawn

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this pilot study is to evaluate the addition of carvedilol with standard of care treatment to determine if it will improve progression-free survival in the front line setting in patients with glioblastoma multiforme (GBM). In addition, monitoring of circulating tumor cells (CTCs) by a real-time reverse transcriptase polymerase chain reaction (qRT-PCR) assay to correlate with the clinical findings.

Phase:

Early Phase 1

Details

Lead Sponsor:

West Virginia University

Collaborators:

NovoCure Ltd.
West Virginia Clinical and Translational Science Institute

Treatments:

Carvedilol